Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: An IQ Consortium PK-PD Discussion Group perspective

Wong, Harvey and Bohnert, Tonika and Damian-Iordache, Valeriu and Gibson, Christopher and Hsu, Cheng-Pang and Krishnatry, Anu Shilpa and Liederer, Bianca M and Lin, Jing and Lu, Qiang and Mettetal, Jerome T and Mudra, Daniel R and Nijsen, Marjoleen JMA and Schroeder, Patricia and Schuck, Edgar and Suryawanshi, Satyendra and Trapa, Patrick and Tsai, Alice and Wang, Haiqing and Wu, Fan (2017) Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: An IQ Consortium PK-PD Discussion Group perspective. Drug Discovery Today. ISSN 18785832

Abstract

With inadequate efficacy being the primary cause for the attrition of drug candidates in clinical development, the need to better predict clinical efficacy earlier in the drug development process has increased in importance in the pharmaceutical industry. Here, we review current applications of translational pharmacokinetic-pharmacodynamic (PK-PD) modeling of preclinical data in the pharmaceutical industry, including best practices. Preclinical translational PK-PD modeling has been used in many therapeutic areas and has been impactful to drug development. The role of preclinical translational PK-PD modeling in drug discovery and development will continue to evolve and broaden, given that its broad implementation in the pharmaceutical industry is relatively recent and many opportunities still exist for its further application.

Item Type: Article
Date Deposited: 19 Sep 2017 00:45
Last Modified: 25 Jan 2019 00:45
URI: https://oak.novartis.com/id/eprint/31544

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.